Advanced assessment through intact glycopeptide analysis of Infliximab's biologics and biosimilar.
Ontology highlight
ABSTRACT: Characterization of therapeutic monoclonal antibodies (mAbs) represents a major challenge for analytical sciences due to their heterogeneity associated with post-translational modifications (PTMs). The protein glycosylation requires comprehensive identification, which could influence on the mAbs' structure and their function. Here, we demonstrated high-resolution tandem mass spectrometry with an ultra-high-performance liquid chromatography for characterization and comparison between biologics and biosimilar of infliximab at an advanced level. Comparing the N- and O-glycopeptides profiles, a total of 49 and 54 glycopeptides was identified for each product of the biologics and biosimilar, respectively. We also discovered one novel N-glycosylation site at the light chain from both biopharmace
SUBMITTER: Kim H
PROVIDER: S-EPMC9745114 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA